(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 February 2016 (04.02.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/019341 A1

(51) International Patent Classification:
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2015/043300

(22) International Filing Date:
31 July 2015 (31.07.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/032,430	1 August 2014 (01.08.2014)	US
62/119,668	23 February 2015 (23.02.2015)	US
62/127,484	3 March 2015 (03.03.2015)	US

(71) Applicant: **PHARMACYCLICS LLC** [US/US]; 995 East Arques Avenue, Sunnyvale, California 94085 (US).

(72) Inventors: **SCHWEIGHOFER, Karl**; 995 East Arques Avenue, Sunnyvale, California 94085 (US). **ECKERT, Karl**; 995 East Arques Avenue, Sunnyvale, California 94085 (US). **KUO, Hsu-Ping**; 125 Connemara Way, Apt. 72, Sunnyvale, California 94087 (US). **CHANG, Betty**; 10375 Lindsay Avenue, Cupertino, California 95014 (US). **BEAUPRE, Darrin**; 512 De Carli Court, Campbell, California 95008 (US). **CHEUNG, Leo**; 38642 Aurora Terrace, Fremont, California 94536 (US).


(74) Agent: **HOSTETLER, Michael J.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR

Fig. 2



(57) Abstract: Disclosed herein, are methods, systems, compositions, arrays, and kits for using biomarkers or biomarker genes (e.g. *EP300, MLL2, BCL-2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9*, CD79B, MYD88, and ROS1) or biomarker gene expression levels for stratifying a patient having a hematological malignancy such as DLBCL for treatment, and administering a TEC inhibitor to selected patients. Also disclosed herein are methods, systems, compositions, arrays, and kits for using biomarkers, biomarker genes, or biomarker gene expresison levels for monitoring a patient during treatment of a hematological malignancy such as DLBCL or FL or for optimizing a treatment regimen with a TEC inhibitor.

WO 2016/019341 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*